๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Heilongjiang
Clinical trial register · China

Clinical Trials in Heilongjiang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Heilongjiang

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring
NCT07747701Acute Ischemic Stroke, Cerebral Autoregulation
Beijing Shijitan Hospital, Capital Medical University
Not applicable
227
Beijing, Dalian, Heilongjiang, Shandong
2026-07-31
Not yet open
Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
NCT07610434IBS, Diarrhea Predominant
Beijing Hospital of Traditional Chinese Medicine
Phase 3
636
Beijing, Chengdu, Chongqing, Guangzhou, Guizhou, Haozhou, Hebei, Heilongjiang
2026-05-31
Recruiting
Efficacy and Safety of PCSK9 Inhibitors in Patients With Large-Artery Atherosclerosis (LAA) Ischemic Stroke
NCT07540741Acute Ischemic Stroke
First Affiliated Hospital of Harbin Medical University
Observational
1,000
Heilongjiang
2025-12-03
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
NCT06924606Advanced NSCLC
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
66
Beijing, Jilin City, Hunan, Sichuan, Chongqing, Guangdong, Heilongjiang, Anyang
2025-07-15
Not yet open
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286HBV, HCC
Peking University First Hospital
Observational
1,500
Heilongjiang, Yizheng, Changle, Junxian, Pingdu, Zouping, Huozhou, Jiexiu
2025-06
Recruiting
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
NCT06832982Advanced Solid Tumors
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Active, closed
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
NCT06666855Open Angle Glaucoma, Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
Phase 3
345
Beijing, Guangzhou, Guiyang, Hangzhou, Heilongjiang, Jinan, Lanzhou, Luoyang
2024-11-28
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Heilongjiang, Jinan
2024-06-29
Active, closed
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485Advanced Solid Tumor
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Active, closed
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 3
605
Beijing, Changsha, Hangzhou, Hangzou, Heilongjiang, Henan, Hubei, Nanjing
2020-12-21
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/heilongjiang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Heilongjiang.

How many clinical trials are recruiting in Heilongjiang?

7 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Heilongjiang), 13 studies
PhaseStudiesRecruitingShare
Phase 35138.5%
Phase 13223.1%
Observational2115.4%
Not applicable117.7%
Phase 1/2117.7%
Phase 2117.7%

Most active sponsors

Lead sponsors with the most studies (Heilongjiang)
Lead sponsorStudiesRecruiting
Daiichi Sankyo20
ArriVent BioPharma, Inc.11
AstraZeneca10
Beijing Hospital of Traditional Chinese Medicine10
Beijing Shijitan Hospital, Capital Medical University11
First Affiliated Hospital of Harbin Medical University11
Peking University First Hospital10
Santen Pharmaceutical Co., Ltd.10
Shanghai Junshi Bioscience Co., Ltd.11
Shanghai Pushi Medical Science Co. Ltd11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.